These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 23079690

  • 21. Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
    Ilter E, Karalok H, Tufekci EC, Batur O.
    Climacteric; 2006 Apr; 9(2):129-34. PubMed ID: 16698659
    [Abstract] [Full Text] [Related]

  • 22. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S, Lorenc RS, Wenderoth D, Stoner KJ, Eusebio R, Orwoll ES.
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [Abstract] [Full Text] [Related]

  • 23. A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
    Clemmesen B, Ravn P, Zegels B, Taquet AN, Christiansen C, Reginster JY.
    Osteoporos Int; 1997 Sep; 7(5):488-95. PubMed ID: 9425508
    [Abstract] [Full Text] [Related]

  • 24. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H.
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [Abstract] [Full Text] [Related]

  • 25. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
    Roux C, Hofbauer LC, Ho PR, Wark JD, Zillikens MC, Fahrleitner-Pammer A, Hawkins F, Micaelo M, Minisola S, Papaioannou N, Stone M, Ferreira I, Siddhanti S, Wagman RB, Brown JP.
    Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
    Kishimoto H, Fukunaga M, Kushida K, Shiraki M, Itabashi A, Nawata H, Nakamura T, Ohta H, Takaoka K, Ohashi Y, Risedronate Phase III Research Group.
    J Bone Miner Metab; 2006 Jan; 24(5):405-13. PubMed ID: 16937274
    [Abstract] [Full Text] [Related]

  • 27. Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
    Ringe JD, Möller G.
    Rheumatol Int; 2009 Dec; 30(2):213-21. PubMed ID: 19430791
    [Abstract] [Full Text] [Related]

  • 28. Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
    Mok CC, Tong KH, To CH, Siu YP, Ma KM.
    Osteoporos Int; 2008 Mar; 19(3):357-64. PubMed ID: 18038273
    [Abstract] [Full Text] [Related]

  • 29. Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
    Palomba S, Orio F, Manguso F, Falbo A, Russo T, Tolino A, Tauchmanovà L, Colao A, Doldo P, Mastrantonio P, Zullo F.
    Osteoporos Int; 2005 Sep; 16(9):1141-9. PubMed ID: 15928801
    [Abstract] [Full Text] [Related]

  • 30. Risedronate on two consecutive days per month.
    Frampton JE.
    Drugs Aging; 2009 Sep; 26(4):355-62. PubMed ID: 19476402
    [Abstract] [Full Text] [Related]

  • 31. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM, Hosking D, Kendler D, Brandi ML, Wark JD, Weryha G, Marques-Neto JF, Gaines KA, Verbruggen N, Melton ME.
    Clin Drug Investig; 2006 Sep; 26(2):63-74. PubMed ID: 17163237
    [Abstract] [Full Text] [Related]

  • 32. The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
    Leung JY, Ho AY, Ip TP, Lee G, Kung AW.
    Bone; 2005 Feb; 36(2):358-64. PubMed ID: 15780963
    [Abstract] [Full Text] [Related]

  • 33. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 34. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN, HORIZON investigators.
    Lancet; 2009 Apr 11; 373(9671):1253-63. PubMed ID: 19362675
    [Abstract] [Full Text] [Related]

  • 35. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
    Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD.
    JAMA; 1999 Oct 13; 282(14):1344-52. PubMed ID: 10527181
    [Abstract] [Full Text] [Related]

  • 36. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP, Kendler DL, McClung MR, Emkey RD, Adachi JD, Bolognese MA, Li Z, Balske A, Lindsay R.
    Calcif Tissue Int; 2002 Aug 13; 71(2):103-11. PubMed ID: 12085156
    [Abstract] [Full Text] [Related]

  • 37. Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
    Sebba AI, Bonnick SL, Kagan R, Thompson DE, Skalky CS, Chen E, de Papp AE, Fosamax Actonel Comparison Trial investigators.
    Curr Med Res Opin; 2004 Dec 13; 20(12):2031-41. PubMed ID: 15706659
    [Abstract] [Full Text] [Related]

  • 38. Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
    Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.
    Int J Radiat Oncol Biol Phys; 2013 Apr 01; 85(5):1239-45. PubMed ID: 23265571
    [Abstract] [Full Text] [Related]

  • 39. Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
    Emkey R.
    MedGenMed; 2004 Jul 19; 6(3):6. PubMed ID: 15520628
    [Abstract] [Full Text] [Related]

  • 40. Risedronate once a week.
    White NJ, Perry CM.
    Treat Endocrinol; 2003 Jul 19; 2(6):415-20; discussion 421. PubMed ID: 15981945
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.